We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+24.05%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$59.8M
AUM Growth
+$23.6M
(+65%)
Cap. Flow
+$14.7M
Cap. Flow
% of AUM
24.55%
Top 10 Holdings %
Top 10 Hldgs %
72.36%
Holding
33
New
10
Increased
11
Reduced
3
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Inogen
INGN
|
+$5.43M |
| 2 |
Gilead Sciences
GILD
|
+$4.64M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$2.88M |
| 4 |
Illumina
ILMN
|
+$2.49M |
| 5 |
Centene
CNC
|
+$1.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$5.66M |
| 2 |
Incyte
INCY
|
+$2.01M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$1.47M |
| 4 |
DaVita
DVA
|
+$1.09M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$1.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PTLA
1
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $6.38M | 10.66% |
183,902
+13,773
| +8% | +$397K |
|
2
PTC Therapeutics
PTCT
$6.25B
| $5.75M | 9.61% |
152,828
+42,034
| +38% | +$1.41M |
|
|
3
Inogen
INGN
$174M
| $5.11M | 8.54% |
53,575
+43,503
| +432% | +$5.43M |
|
|
4
Gilead Sciences
GILD
$167B
| $4.54M | 7.59% |
+69,879
| New | +$4.64M |
|
|
GBT
5
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.53M | 7.58% |
85,661
-21,023
| -20% | -$1.03M |
|
|
6
Insmed
INSM
$22.6B
| $4.5M | 7.52% |
154,887
-218,311
| -58% | -$5.66M |
|
|
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
| $3.4M | 5.69% |
71,675
+14,189
| +25% | +$625K |
|
|
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $3.25M | 5.44% |
+62,561
| New | +$2.88M |
|
|
9
Centene
CNC
$31.6B
| $3.14M | 5.24% |
59,093
+26,715
| +83% | +$1.62M |
|
10
UnitedHealth
UNH
$389B
| $2.69M | 4.49% |
10,864
+3,980
| +58% | +$1.01M |
|
|
11
Illumina
ILMN
$29.2B
| $2.58M | 4.32% |
+8,551
| New | +$2.49M |
|
|
CBIO
12
Crescent Biopharma
CBIO
$608M
| $1.71M | 2.85% |
+1,370
| New | +$1.57M |
|
13
Heron Therapeutics
HRTX
$92M
| $1.66M | 2.77% |
67,909
+37,048
| +120% | +$970K |
|
14
Penumbra
PEN
$12.6B
| $1.65M | 2.76% |
11,254
+1,288
| +13% | +$184K |
|
|
XLRN
15
DELISTED
Acceleron Pharma
XLRN
| $1.4M | 2.34% |
30,125
+11,561
| +62% | +$508K |
|
16
CVS Health
CVS
$140B
| $1.02M | 1.71% |
28,680
+6,941
| +32% | +$428K |
|
17
Alkermes
ALKS
$8.42B
| $1.01M | 1.69% |
+27,673
| New | +$914K |
|
18
iRhythm Holdings
IRTC
$3.86B
| $823K | 1.38% |
+10,978
| New | +$938K |
|
19
Alnylam Pharmaceuticals
ALNY
$38.5B
| $818K | 1.37% |
+8,754
| New | +$732K |
|
|
NCNA
20
NuCana
NCNA
$5.37M
| $772K | 1.29% |
9
| – | – |
|
21
Verrica Pharmaceuticals
VRCA
$92.8M
| $762K | 1.27% |
7,046
+758
| +12% | +$87.4K |
|
22
Natera
NTRA
$36.1B
| $628K | 1.05% |
+30,458
| New | +$477K |
|
|
VRAY
23
DELISTED
ViewRay, Inc.
VRAY
| $618K | 1.03% |
83,611
-13,353
| -14% | -$103K |
|
24
Twist Bioscience
TWST
$5.51B
| $550K | 0.92% |
+23,733
| New | +$536K |
|
25
Pacira BioSciences
PCRX
$1.05B
| $528K | 0.88% |
+13,881
| New | +$542K |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Asymmetry Capital Management held 33 positions worth $59.8M, up 65% from $36.2M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Asymmetry Capital Management deployed $14.7M of net new capital in Q1 2019, opening 10 new positions and adding to 11 existing holdings. Its largest new stake was Gilead Sciences: 69,879 shares worth $4.54M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 83% a quarter earlier.
On the sell side, the largest reduction was Insmed, an estimated $5.66M trimmed.
- Asymmetry Capital Management's largest Q1 2019 buy was Gilead Sciences: 69,879 shares worth $4.54M.
- Asymmetry Capital Management added most to Inogen in Q1 2019, an estimated $5.43M increase.
- Asymmetry Capital Management's biggest Q1 2019 reduction was Insmed, cutting an estimated $5.66M.
- Asymmetry Capital Management fully exited Incyte in Q1 2019, selling an estimated $2.01M.
- Asymmetry Capital Management's ten largest holdings make up 72% of its $59.8M portfolio in Q1 2019.
- Asymmetry Capital Management opened 10 new positions and closed 8 in Q1 2019.
- Asymmetry Capital Management's portfolio value rose 65% quarter-over-quarter to $59.8M.
Based on Asymmetry Capital Management's 13F filing for Q1 2019, filed 8 May 2019.